BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32
BALAXI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Balaxi Pharmaceuticals has submitted a quarterly compliance statement confirming how it used money raised through a preferential issue of convertible warrants and equity shares. The company had raised a total of about Rs. 47.57 crore between October 2022 and April 2024, primarily to fund the construction of its first pharmaceutical formulation plant at Jadcherla, Hyderabad, along with working capital and general corporate purposes. During the quarter ended March 31, 2025, the company utilised Rs. 19.89 crore towards the stated objectives. The filing confirms there is no deviation or variation from the originally disclosed purpose of fund use, with no comments from the audit committee or auditors.
This is a routine compliance filing and carries a mildly positive signal — it confirms the company is using the funds as promised to investors without any diversion. Shareholders can take comfort from the transparency, though the filing itself is unlikely to move the stock price meaningfully.